{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T09:52:51Z","timestamp":1743155571646,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":90,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071618837"},{"type":"electronic","value":"9781071618844"}],"license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-1884-4_11","type":"book-chapter","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T16:04:44Z","timestamp":1639670684000},"page":"229-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases"],"prefix":"10.1007","author":[{"given":"Ziyang","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devivasha","family":"Bordoloi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Kudchodkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makan","family":"Khoshnejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Giron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faraz","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moonsup","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young K.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Maslow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Abdel-Mohsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kar","family":"Muthumani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"issue":"2","key":"11_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S1473-3099(18)30541-3","volume":"19","author":"HS Marshall","year":"2019","unstructured":"Marshall HS, Plotkin S (2019) The changing epidemiology of mumps in a high vaccination era. Lancet Infect Dis 19(2):118\u2013119. https:\/\/doi.org\/10.1016\/S1473-3099(18)30541-3","journal-title":"Lancet Infect Dis"},{"issue":"28","key":"11_CR2","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1016\/j.vaccine.2019.07.101","volume":"38","author":"WC Koff","year":"2020","unstructured":"Koff WC, Schenkelberg T (2020) The future of vaccine development. Vaccines 38(28):4485\u20134486. https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.101","journal-title":"Vaccines"},{"issue":"7","key":"11_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/ni.2871","volume":"15","author":"WC Koff","year":"2014","unstructured":"Koff WC, Gust ID, Plotkin SA (2014) Toward a human vaccines project. Nat Immunol 15(7):589\u2013592. https:\/\/doi.org\/10.1038\/ni.2871","journal-title":"Nat Immunol"},{"issue":"7","key":"11_CR4","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1080\/21645515.2017.1412024","volume":"14","author":"G Wong","year":"2018","unstructured":"Wong G, Qiu X (2018) Funding vaccines for emerging infectious diseases. Hum Vaccin Immunother 14(7):1760\u20131762. https:\/\/doi.org\/10.1080\/21645515.2017.1412024","journal-title":"Hum Vaccin Immunother"},{"issue":"46","key":"11_CR5","doi-asserted-by":"publisher","first-page":"eabb8618","DOI":"10.1126\/sciimmunol.abb8618","volume":"5","author":"SE Henrickson","year":"2020","unstructured":"Henrickson SE (2020) Learning from our immunological history: what can SARS-CoV teach us about SARS-CoV-2? Sci Immunol 5(46):eabb8618. https:\/\/doi.org\/10.1126\/sciimmunol.abb8618","journal-title":"Sci Immunol"},{"issue":"10","key":"11_CR6","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMoa2001191","volume":"382","author":"ML Holshue","year":"2020","unstructured":"Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382(10):929\u2013936. https:\/\/doi.org\/10.1056\/NEJMoa2001191","journal-title":"N Engl J Med"},{"issue":"8","key":"11_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016) SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14(8):523\u2013534. https:\/\/doi.org\/10.1038\/nrmicro.2016.81","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"11_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","volume":"26","author":"KG Andersen","year":"2020","unstructured":"Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (2020) The proximal origin of SARS-CoV-2. Nat Med 26(4):450\u2013452. https:\/\/doi.org\/10.1038\/s41591-020-0820-9","journal-title":"Nat Med"},{"issue":"9","key":"11_CR9","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1016\/j.vaccine.2019.10.046","volume":"38","author":"SA Plotkin","year":"2020","unstructured":"Plotkin SA (2020) Updates on immunologic correlates of vaccine-induced protection. Vaccines 38(9):2250\u20132257. https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.046","journal-title":"Vaccines"},{"issue":"9","key":"11_CR10","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJMp2006761","volume":"383","author":"WC Koff","year":"2020","unstructured":"Koff WC, Williams MA (2020) Covid-19 and immunity in aging populations - a new research agenda. N Engl J Med 383(9):804\u2013805. https:\/\/doi.org\/10.1056\/NEJMp2006761","journal-title":"N Engl J Med"},{"issue":"10223","key":"11_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507\u2013513. https:\/\/doi.org\/10.1016\/S0140-6736(20)30211-7","journal-title":"Lancet"},{"issue":"6498","key":"11_CR12","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.abb8001","volume":"368","author":"J Zhang","year":"2020","unstructured":"Zhang J, Litvinova M, Liang Y, Wang Y, Wang W, Zhao S et al (2020) Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. Science 368(6498):1481\u20131486. https:\/\/doi.org\/10.1126\/science.abb8001","journal-title":"Science"},{"issue":"1","key":"11_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00103-019-03061-2","volume":"63","author":"V Bernasconi","year":"2020","unstructured":"Bernasconi V, Kristiansen PA, Whelan M, Roman RG, Bettis A, Yimer SA et al (2020) Developing vaccines against epidemic-prone emerging infectious diseases. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 63(1):65\u201373. https:\/\/doi.org\/10.1007\/s00103-019-03061-2","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"},{"issue":"6","key":"11_CR14","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","volume":"52","author":"L Ni","year":"2020","unstructured":"Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H et al (2020) Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 52(6):971\u20137.e3. https:\/\/doi.org\/10.1016\/j.immuni.2020.04.023","journal-title":"Immunity"},{"issue":"9","key":"11_CR15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","volume":"19","author":"K Modjarrad","year":"2019","unstructured":"Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K et al (2019) Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis 19(9):1013\u20131022. https:\/\/doi.org\/10.1016\/S1473-3099(19)30266-X","journal-title":"Lancet Infect Dis"},{"key":"11_CR16","doi-asserted-by":"publisher","unstructured":"Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI et al (2017) Safety and immunogenicity of an anti-zika virus DNA vaccine - preliminary report. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1708120","DOI":"10.1056\/NEJMoa1708120"},{"issue":"1","key":"11_CR17","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","volume":"11","author":"TRF Smith","year":"2020","unstructured":"Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J et al (2020) Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun 11(1):2601. https:\/\/doi.org\/10.1038\/s41467-020-16505-0","journal-title":"Nat Commun"},{"issue":"5","key":"11_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nbt0516-449","volume":"34","author":"JM Perkel","year":"2016","unstructured":"Perkel JM (2016) NIH dengue vaccine leaps into phase 3 studies. Nat Biotechnol 34(5):449. https:\/\/doi.org\/10.1038\/nbt0516-449","journal-title":"Nat Biotechnol"},{"issue":"2","key":"11_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nm.4253","volume":"23","author":"JH Erasmus","year":"2017","unstructured":"Erasmus JH, Auguste AJ, Kaelber JT, Luo H, Rossi SL, Fenton K et al (2017) A chikungunya fever vaccine utilizing an insect-specific virus platform. Nat Med 23(2):192\u2013199. https:\/\/doi.org\/10.1038\/nm.4253","journal-title":"Nat Med"},{"issue":"1","key":"11_CR20","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41598-017-00798-1","volume":"7","author":"M Kongsgaard","year":"2017","unstructured":"Kongsgaard M, Bassi MR, Rasmussen M, Skj\u00f8dt K, Thybo S, Gabriel M et al (2017) Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination. Sci Rep 7(1):662. https:\/\/doi.org\/10.1038\/s41598-017-00798-1","journal-title":"Sci Rep"},{"issue":"4","key":"11_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/ni.2844","volume":"15","author":"AJ McMichael","year":"2014","unstructured":"McMichael AJ, Koff WC (2014) Vaccines that stimulate T cell immunity to HIV-1: the next step. Nat Immunol 15(4):319\u2013322. https:\/\/doi.org\/10.1038\/ni.2844","journal-title":"Nat Immunol"},{"issue":"41","key":"11_CR22","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1016\/j.vaccine.2017.02.015","volume":"35","author":"JN Maslow","year":"2017","unstructured":"Maslow JN (2017) Vaccine development for emerging virulent infectious diseases. Vaccines 35(41):5437\u20135443. https:\/\/doi.org\/10.1016\/j.vaccine.2017.02.015","journal-title":"Vaccines"},{"key":"11_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3389\/fimmu.2013.00354","volume":"4","author":"S Flingai","year":"2013","unstructured":"Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB (2013) Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol 4:354. https:\/\/doi.org\/10.3389\/fimmu.2013.00354","journal-title":"Front Immunol"},{"issue":"11","key":"11_CR24","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.3390\/ijms19113605","volume":"19","author":"D Hobernik","year":"2018","unstructured":"Hobernik D, Bros M (2018) DNA vaccines-how far from clinical use? Int J Mol Sci 19(11):3605. https:\/\/doi.org\/10.3390\/ijms19113605","journal-title":"Int J Mol Sci"},{"key":"11_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.coi.2020.01.006","volume":"65","author":"EN Gary","year":"2020","unstructured":"Gary EN, Weiner DB (2020) DNA vaccines: prime time is now. Curr Opin Immunol 65:21\u201327. https:\/\/doi.org\/10.1016\/j.coi.2020.01.006","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"11_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1586\/erv.11.188","volume":"11","author":"F Saade","year":"2012","unstructured":"Saade F, Petrovsky N (2012) Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 11(2):189\u2013209. https:\/\/doi.org\/10.1586\/erv.11.188","journal-title":"Expert Rev Vaccines"},{"key":"11_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ebiom.2018.08.027","volume":"35","author":"Z Xu","year":"2018","unstructured":"Xu Z, Wise MC, Choi H, Perales-Puchalt A, Patel A, Tello-Ruiz E et al (2018) Synthetic DNA delivery by electroporation promotes robust in vivo sulfation of broadly neutralizing anti-HIV immunoadhesin eCD4-Ig. EBioMedicine 35:97\u2013105. https:\/\/doi.org\/10.1016\/j.ebiom.2018.08.027","journal-title":"EBioMedicine"},{"issue":"35","key":"11_CR28","doi-asserted-by":"publisher","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","volume":"114","author":"J Pallesen","year":"2017","unstructured":"Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL et al (2017) Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A 114(35):E7348\u2013E7E57. https:\/\/doi.org\/10.1073\/pnas.1707304114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"11_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1073\/pnas.1819612116","volume":"116","author":"R Rappuoli","year":"2019","unstructured":"Rappuoli R, De Gregorio E, Costantino P (2019) On the mechanisms of conjugate vaccines. Proc Natl Acad Sci U S A 116(1):14\u201316. https:\/\/doi.org\/10.1073\/pnas.1819612116","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"11_CR30","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41591-020-0769-8","volume":"26","author":"Y Kotliarov","year":"2020","unstructured":"Kotliarov Y, Sparks R, Martins AJ, Mule MP, Lu Y, Goswami M et al (2020) Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy individuals and disease activity in patients with lupus. Nat Med 26(4):618\u2013629. https:\/\/doi.org\/10.1038\/s41591-020-0769-8","journal-title":"Nat Med"},{"issue":"10120","key":"11_CR31","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","volume":"391","author":"MR Gaudinski","year":"2018","unstructured":"Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS et al (2018) Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 391(10120):552\u2013562. https:\/\/doi.org\/10.1016\/S0140-6736(17)33105-7","journal-title":"Lancet"},{"issue":"1","key":"11_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/vaccines8010056","volume":"8","author":"C Aggarwal","year":"2020","unstructured":"Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Cheung J et al (2020) Immune therapy targeting E6\/E7 oncogenes of human papillomavirus type 6 (HPV-6) reduces or eliminates the need for surgical intervention in the treatment of HPV-6 associated recurrent respiratory papillomatosis. Vaccines (Basel) 8(1):56. https:\/\/doi.org\/10.3390\/vaccines8010056","journal-title":"Vaccines (Basel)"},{"issue":"6505","key":"11_CR33","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH et al (2020) DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369(6505):806\u2013811. https:\/\/doi.org\/10.1126\/science.abc6284","journal-title":"Science"},{"issue":"11","key":"11_CR34","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1172\/JCI128699","volume":"129","author":"NG Rouphael","year":"2019","unstructured":"Rouphael NG, Morgan C, Li SS, Jensen R, Sanchez B, Karuna S et al (2019) DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. J Clin Invest 129(11):4769\u20134785. https:\/\/doi.org\/10.1172\/JCI128699","journal-title":"J Clin Invest"},{"issue":"8","key":"11_CR35","doi-asserted-by":"publisher","first-page":"e126086","DOI":"10.1172\/jci.insight.126086","volume":"4","author":"A Perales-Puchalt","year":"2019","unstructured":"Perales-Puchalt A, Duperret EK, Yang X, Hernandez P, Wojtak K, Zhu X et al (2019) DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity. JCI Insight 4(8):e126086. https:\/\/doi.org\/10.1172\/jci.insight.126086","journal-title":"JCI Insight"},{"issue":"301","key":"11_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac7462","volume":"7","author":"K Muthumani","year":"2015","unstructured":"Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO et al (2015) A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med 7(301):301ra132. https:\/\/doi.org\/10.1126\/scitranslmed.aac7462","journal-title":"Sci Transl Med"},{"issue":"1","key":"11_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000928","volume":"5","author":"K Mallilankaraman","year":"2011","unstructured":"Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, Ramanathan AA et al (2011) A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 5(1):e928. https:\/\/doi.org\/10.1371\/journal.pntd.0000928","journal-title":"PLoS Negl Trop Dis"},{"key":"11_CR38","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1172\/JCI132779","volume":"130","author":"MC Wise","year":"2020","unstructured":"Wise MC, Xu Z, Tello-Ruiz E, Beck C, Trautz A, Patel A et al (2020) In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity. J Clin Invest 130:827. https:\/\/doi.org\/10.1172\/JCI132779","journal-title":"J Clin Invest"},{"issue":"6","key":"11_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003420","volume":"9","author":"S Sampath","year":"2013","unstructured":"Sampath S, Carrico C, Janes J, Gurumoorthy S, Gibson C, Melcher M et al (2013) Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development. PLoS Pathog 9(6):e1003420. https:\/\/doi.org\/10.1371\/journal.ppat.1003420","journal-title":"PLoS Pathog"},{"key":"11_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.coi.2019.03.003","volume":"59","author":"Z Xu","year":"2019","unstructured":"Xu Z, Kulp DW (2019) Protein engineering and particulate display of B-cell epitopes to facilitate development of novel vaccines. Curr Opin Immunol 59:49\u201356. https:\/\/doi.org\/10.1016\/j.coi.2019.03.003","journal-title":"Curr Opin Immunol"},{"issue":"6483","key":"11_CR41","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O et al (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367(6483):1260\u20131263. https:\/\/doi.org\/10.1126\/science.abb2507","journal-title":"Science"},{"issue":"9","key":"11_CR42","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nm.3927","volume":"21","author":"HM Yassine","year":"2015","unstructured":"Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP et al (2015) Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21(9):1065\u20131070. https:\/\/doi.org\/10.1038\/nm.3927","journal-title":"Nat Med"},{"issue":"2","key":"11_CR43","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.immuni.2018.07.005","volume":"49","author":"H Duan","year":"2018","unstructured":"Duan H, Chen X, Boyington JC, Cheng C, Zhang Y, Jafari AJ et al (2018) Glycan masking focuses immune responses to the HIV-1 CD4-binding site and enhances elicitation of VRC01-class precursor antibodies. Immunity 49(2):301\u201311.e5. https:\/\/doi.org\/10.1016\/j.immuni.2018.07.005","journal-title":"Immunity"},{"issue":"1","key":"11_CR44","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41467-017-01549-6","volume":"8","author":"DW Kulp","year":"2017","unstructured":"Kulp DW, Steichen JM, Pauthner M, Hu X, Schiffner T, Liguori A et al (2017) Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nat Commun 8(1):1655. https:\/\/doi.org\/10.1038\/s41467-017-01549-6","journal-title":"Nat Commun"},{"issue":"8","key":"11_CR45","doi-asserted-by":"publisher","first-page":"1902802","DOI":"10.1002\/advs.201902802","volume":"7","author":"Z Xu","year":"2020","unstructured":"Xu Z, Wise MC, Chokkalingam N, Walker S, Tello-Ruiz E, Elliott STC et al (2020) In vivo assembly of nanoparticles achieved through synergy of structure-based protein engineering and synthetic DNA generates enhanced adaptive immunity. Adv Sci 7(8):1902802. https:\/\/doi.org\/10.1002\/advs.201902802","journal-title":"Adv Sci"},{"issue":"6244","key":"11_CR46","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1126\/science.aac5894","volume":"349","author":"JG Jardine","year":"2015","unstructured":"Jardine JG, Ota T, Sok D, Pauthner M, Kulp DW, Kalyuzhniy O et al (2015) HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349(6244):156\u2013161. https:\/\/doi.org\/10.1126\/science.aac5894","journal-title":"Science"},{"issue":"8","key":"11_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135392","volume":"10","author":"JE Gilda","year":"2015","unstructured":"Gilda JE, Ghosh R, Cheah JX, West TM, Bodine SC, Gomes AV (2015) Western blotting inaccuracies with unverified antibodies: need for a western blotting minimal reporting standard (WBMRS). PLoS One 10(8):e0135392. https:\/\/doi.org\/10.1371\/journal.pone.0135392","journal-title":"PLoS One"},{"key":"11_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/B978-0-12-387718-5.00004-3","volume":"101","author":"D Martins-de-Souza","year":"2011","unstructured":"Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N, Harris LW, Bahn S (2011) Proteomic technologies for biomarker studies in psychiatry: advances and needs. Int Rev Neurobiol 101:65\u201394. https:\/\/doi.org\/10.1016\/B978-0-12-387718-5.00004-3","journal-title":"Int Rev Neurobiol"},{"key":"11_CR49","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0076-6879(09)63033-0","volume":"463","author":"A Alegria-Schaffer","year":"2009","unstructured":"Alegria-Schaffer A, Lodge A, Vattem K (2009) Performing and optimizing Western blots with an emphasis on chemiluminescent detection. Methods Enzymol 463:573\u2013599. https:\/\/doi.org\/10.1016\/S0076-6879(09)63033-0","journal-title":"Methods Enzymol"},{"key":"11_CR50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/B978-0-12-803109-4.00004-0","volume":"2017","author":"S Payne","year":"2017","unstructured":"Payne S (2017) Methods to study viruses. Viruses 2017:37\u201352. https:\/\/doi.org\/10.1016\/B978-0-12-803109-4.00004-0","journal-title":"Viruses"},{"issue":"4","key":"11_CR51","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/21645515.2019.1688038","volume":"16","author":"H Choi","year":"2020","unstructured":"Choi H, Kudchodkar SB, Reuschel EL, Asija K, Borole P, Agarwal S et al (2020) Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge. Hum Vaccin Immunother 16(4):907\u2013918. https:\/\/doi.org\/10.1080\/21645515.2019.1688038","journal-title":"Hum Vaccin Immunother"},{"key":"11_CR52","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1080\/21645515.2020.1763686","volume":"16","author":"US Zankharia","year":"2020","unstructured":"Zankharia US, Kudchodkar S, Khoshnejad M, Perales-Puchalt A, Choi H, Ho M et al (2020) Neutralization of hepatitis B virus by a novel DNA-encoded monoclonal antibody. Hum Vaccin Immunother 16:2156\u20132164. https:\/\/doi.org\/10.1080\/21645515.2020.1763686","journal-title":"Hum Vaccin Immunother"},{"key":"11_CR53","first-page":"1503","volume-title":"Principles and practice of infectious diseases","author":"FR Simonetti","year":"2015","unstructured":"Simonetti FR, Dewar R, Maldarelli F (2015) Diagnosis of human immunodeficiency virus infection. In: Bennett JE, Dolin R, Blaser MJ (eds) Principles and practice of infectious diseases, 8th edn. Elsevier, Philadelphia, PA, pp 1503\u201325.e7","edition":"8"},{"issue":"2","key":"11_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007042","volume":"13","author":"H Choi","year":"2019","unstructured":"Choi H, Kudchodkar SB, Reuschel EL, Asija K, Borole P, Ho M et al (2019) Protective immunity by an engineered DNA vaccine for Mayaro virus. PLoS Negl Trop Dis 13(2):e0007042. https:\/\/doi.org\/10.1371\/journal.pntd.0007042","journal-title":"PLoS Negl Trop Dis"},{"issue":"7818","key":"11_CR55","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia SF, Yan LM, Chin AWH, Fung K, Choy KT, Wong AYL et al (2020) Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583(7818):834\u2013838. https:\/\/doi.org\/10.1038\/s41586-020-2342-5","journal-title":"Nature"},{"issue":"6","key":"11_CR56","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1128\/JVI.03473-14","volume":"89","author":"P Pugach","year":"2015","unstructured":"Pugach P, Ozorowski G, Cupo A, Ringe R, Yasmeen A, de Val N et al (2015) A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J Virol 89(6):3380\u20133395. https:\/\/doi.org\/10.1128\/JVI.03473-14","journal-title":"J Virol"},{"issue":"1","key":"11_CR57","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/22221751.2020.1745093","volume":"9","author":"Q Wang","year":"2020","unstructured":"Wang Q, Ma B, Liang Q, Zhu A, Wang H, Fu L et al (2020) Stabilized diverse HIV-1 envelope trimers for vaccine design. Emerg Microbes Infect 9(1):775\u2013786. https:\/\/doi.org\/10.1080\/22221751.2020.1745093","journal-title":"Emerg Microbes Infect"},{"issue":"11\u201312","key":"11_CR58","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.micinf.2018.03.001","volume":"20","author":"SB Kudchodkar","year":"2018","unstructured":"Kudchodkar SB, Choi H, Reuschel EL, Esquivel R, Jin-Ah Kwon J, Jeong M et al (2018) Rapid response to an emerging infectious disease - lessons learned from development of a synthetic DNA vaccine targeting Zika virus. Microbes Infect 20(11\u201312):676\u2013684. https:\/\/doi.org\/10.1016\/j.micinf.2018.03.001","journal-title":"Microbes Infect"},{"issue":"1","key":"11_CR59","doi-asserted-by":"publisher","first-page":"15701","DOI":"10.1038\/s41598-018-34171-7","volume":"8","author":"RN Kirchdoerfer","year":"2018","unstructured":"Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA et al (2018) Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci Rep 8(1):15701. https:\/\/doi.org\/10.1038\/s41598-018-34171-7","journal-title":"Sci Rep"},{"issue":"9","key":"11_CR60","doi-asserted-by":"publisher","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","volume":"9","author":"RW Sanders","year":"2013","unstructured":"Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N et al (2013) A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 9(9):e1003618. https:\/\/doi.org\/10.1371\/journal.ppat.1003618","journal-title":"PLoS Pathog"},{"key":"11_CR61","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/978-1-61779-921-1_25","volume":"899","author":"E Sahin","year":"2012","unstructured":"Sahin E, Roberts CJ (2012) Size-exclusion chromatography with multi-angle light scattering for elucidating protein aggregation mechanisms. Methods Mol Biol 899:403\u2013423. https:\/\/doi.org\/10.1007\/978-1-61779-921-1_25","journal-title":"Methods Mol Biol"},{"issue":"20","key":"11_CR62","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1080\/10826076.2012.743724","volume":"35","author":"P Hong","year":"2012","unstructured":"Hong P, Koza S, Bouvier ES (2012) Size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates. J Liq Chromatogr Relat Technol 35(20):2923\u20132950. https:\/\/doi.org\/10.1080\/10826076.2012.743724","journal-title":"J Liq Chromatogr Relat Technol"},{"issue":"13","key":"11_CR63","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1074\/jbc.REV118.005602","volume":"294","author":"D Lyumkis","year":"2019","unstructured":"Lyumkis D (2019) Challenges and opportunities in cryo-EM single-particle analysis. J Biol Chem 294(13):5181\u20135197. https:\/\/doi.org\/10.1074\/jbc.REV118.005602","journal-title":"J Biol Chem"},{"issue":"17","key":"11_CR64","doi-asserted-by":"publisher","first-page":"8954","DOI":"10.1128\/JVI.00754-11","volume":"85","author":"Y Li","year":"2011","unstructured":"Li Y, O\u2019Dell S, Walker LM, Wu X, Guenaga J, Feng Y et al (2011) Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol 85(17):8954\u20138967. https:\/\/doi.org\/10.1128\/JVI.00754-11","journal-title":"J Virol"},{"issue":"4","key":"11_CR65","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.immuni.2017.03.017","volume":"46","author":"JH Lee","year":"2017","unstructured":"Lee JH, Andrabi R, Su CY, Yasmeen A, Julien JP, Kong L et al (2017) A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic beta-hairpin structure. Immunity 46(4):690\u2013702. https:\/\/doi.org\/10.1016\/j.immuni.2017.03.017","journal-title":"Immunity"},{"issue":"2","key":"11_CR66","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.virol.2008.07.007","volume":"380","author":"X Wu","year":"2008","unstructured":"Wu X, Sambor A, Nason MC, Yang ZY, Wu L, Zolla-Pazner S et al (2008) Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses. Virology 380(2):285\u2013295. https:\/\/doi.org\/10.1016\/j.virol.2008.07.007","journal-title":"Virology"},{"key":"11_CR67","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP et al (2020) Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med 383:1544. https:\/\/doi.org\/10.1056\/NEJMoa2024671","journal-title":"N Engl J Med"},{"issue":"7","key":"11_CR68","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17(7):1055\u20131065. https:\/\/doi.org\/10.1128\/CVI.00131-10","journal-title":"Clin Vaccine Immunol"},{"issue":"16","key":"11_CR69","doi-asserted-by":"publisher","first-page":"2000421","DOI":"10.2807\/1560-7917.ES.2020.25.16.2000421","volume":"25","author":"RA Perera","year":"2020","unstructured":"Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC et al (2020) Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill 25(16):2000421. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.16.2000421","journal-title":"Euro Surveill"},{"issue":"1","key":"11_CR70","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L et al (2020) Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells. Cell 182(1):73\u201384.e16. https:\/\/doi.org\/10.1016\/j.cell.2020.05.025","journal-title":"Cell"},{"key":"11_CR71","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fcimb.2018.00335","volume":"8","author":"S Lebourgeois","year":"2018","unstructured":"Lebourgeois S, Fraisse A, Hennechart-Collette C, Guillier L, Perelle S, Martin-Latil S (2018) Development of a real-time cell analysis (RTCA) method as a fast and accurate method for detecting infectious particles of the adapted strain of hepatitis A virus. Front Cell Infect Microbiol 8:335. https:\/\/doi.org\/10.3389\/fcimb.2018.00335","journal-title":"Front Cell Infect Microbiol"},{"key":"11_CR72","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM et al (2014) Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods 409:131\u2013146. https:\/\/doi.org\/10.1016\/j.jim.2013.11.022","journal-title":"J Immunol Methods"},{"issue":"4","key":"11_CR73","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1089\/AID.2016.0142","volume":"33","author":"M Bilska","year":"2017","unstructured":"Bilska M, Tang H, Montefiori DC (2017) Short communication: potential risk of replication-competent virus in HIV-1 Env-pseudotyped virus preparations. AIDS Res Hum Retrovir 33(4):368\u2013372. https:\/\/doi.org\/10.1089\/AID.2016.0142","journal-title":"AIDS Res Hum Retrovir"},{"issue":"8","key":"11_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002890","volume":"8","author":"MD Alpert","year":"2012","unstructured":"Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M Jr, Carville A et al (2012) ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 8(8):e1002890. https:\/\/doi.org\/10.1371\/journal.ppat.1002890","journal-title":"PLoS Pathog"},{"key":"11_CR75","doi-asserted-by":"publisher","first-page":"10844","DOI":"10.1038\/ncomms10844","volume":"7","author":"T Bruel","year":"2016","unstructured":"Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K et al (2016) Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun 7:10844. https:\/\/doi.org\/10.1038\/ncomms10844","journal-title":"Nat Commun"},{"issue":"12","key":"11_CR76","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1016\/j.molimm.2007.02.005","volume":"44","author":"K Masuda","year":"2007","unstructured":"Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M, Kobayashi-Natsume Y et al (2007) Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol 44(12):3122\u20133131. https:\/\/doi.org\/10.1016\/j.molimm.2007.02.005","journal-title":"Mol Immunol"},{"issue":"5","key":"11_CR77","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4161\/mabs.2.5.13078","volume":"2","author":"MF Naso","year":"2010","unstructured":"Naso MF, Tam SH, Scallon BJ, Raju TS (2010) Engineering host cell lines to reduce terminal sialylation of secreted antibodies. MAbs 2(5):519\u2013527. https:\/\/doi.org\/10.4161\/mabs.2.5.13078","journal-title":"MAbs"},{"issue":"2","key":"11_CR78","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/6179","volume":"17","author":"P Umana","year":"1999","unstructured":"Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17(2):176\u2013180. https:\/\/doi.org\/10.1038\/6179","journal-title":"Nat Biotechnol"},{"issue":"7","key":"11_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0020073","volume":"2","author":"H Ebihara","year":"2006","unstructured":"Ebihara H, Takada A, Kobasa D, Jones S, Neumann G, Theriault S et al (2006) Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2(7):e73. https:\/\/doi.org\/10.1371\/journal.ppat.0020073","journal-title":"PLoS Pathog"},{"issue":"1","key":"11_CR80","doi-asserted-by":"publisher","first-page":"3","DOI":"10.24272\/j.issn.2095-8137.2017.052","volume":"39","author":"G Wong","year":"2018","unstructured":"Wong G, Qiu XG (2018) Type I interferon receptor knockout mice as models for infection of highly pathogenic viruses with outbreak potential. Zool Res 39(1):3\u201314. https:\/\/doi.org\/10.24272\/j.issn.2095-8137.2017.052","journal-title":"Zool Res"},{"issue":"7606","key":"11_CR81","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nature18296","volume":"534","author":"FR Cugola","year":"2016","unstructured":"Cugola FR, Fernandes IR, Russo FB, Freitas BC, Dias JL, Guimaraes KP et al (2016) The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534(7606):267\u2013271. https:\/\/doi.org\/10.1038\/nature18296","journal-title":"Nature"},{"issue":"3","key":"11_CR82","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","volume":"182","author":"J Sun","year":"2020","unstructured":"Sun J, Zhuang Z, Zheng J, Li K, Wong RL, Liu D et al (2020) Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 182(3):734\u201343.e5. https:\/\/doi.org\/10.1016\/j.cell.2020.06.010","journal-title":"Cell"},{"issue":"7818","key":"11_CR83","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","volume":"583","author":"L Bao","year":"2020","unstructured":"Bao L, Deng W, Huang B, Gao H, Liu J, Ren L et al (2020) The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583(7818):830\u2013833. https:\/\/doi.org\/10.1038\/s41586-020-2312-y","journal-title":"Nature"},{"issue":"6505","key":"11_CR84","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.abc5343","volume":"369","author":"W Deng","year":"2020","unstructured":"Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J et al (2020) Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 369(6505):818\u2013823. https:\/\/doi.org\/10.1126\/science.abc5343","journal-title":"Science"},{"key":"11_CR85","doi-asserted-by":"crossref","unstructured":"Guebre-Xabier M, Patel N, Tian J-H, Zhou B, Maciejewski S, Lam K et al (2020) NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. BioRxiv:256578","DOI":"10.1101\/2020.08.18.256578"},{"key":"11_CR86","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN et al (2020) An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 383:1920. https:\/\/doi.org\/10.1056\/NEJMoa2022483","journal-title":"N Engl J Med"},{"key":"11_CR87","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2020) Phase 1\/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586:589. https:\/\/doi.org\/10.1038\/s41586-020-2639-4","journal-title":"Nature"},{"issue":"547","key":"11_CR88","doi-asserted-by":"publisher","first-page":"eaaw9066","DOI":"10.1126\/scitranslmed.aaw9066","volume":"12","author":"S Maciejewski","year":"2020","unstructured":"Maciejewski S, Ruckwardt TJ, Morabito KM, Foreman BM, Burgomaster KE, Gordon DN et al (2020) Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Sci Transl Med 12(547):eaaw9066. https:\/\/doi.org\/10.1126\/scitranslmed.aaw9066","journal-title":"Sci Transl Med"},{"issue":"6","key":"11_CR89","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8399","volume":"12","author":"C Manners","year":"2020","unstructured":"Manners C, Larios Bautista E, Sidoti H, Lopez OJ (2020) Protective adaptive immunity against severe acute respiratory syndrome coronaviruses 2 (SARS-CoV-2) and implications for vaccines. Cureus 12(6):e8399. https:\/\/doi.org\/10.7759\/cureus.8399","journal-title":"Cureus"},{"key":"11_CR90","doi-asserted-by":"crossref","unstructured":"van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR et al (2020) ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. BioRxiv:093195","DOI":"10.1101\/2020.05.13.093195"}],"container-title":["Methods in Molecular Biology","Vaccine Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-1884-4_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T11:29:06Z","timestamp":1662118146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-1884-4_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"ISBN":["9781071618837","9781071618844"],"references-count":90,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-1884-4_11","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2021,12,17]]},"assertion":[{"value":"17 December 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}